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A TALE OF TWO STUDIES:A COMPARISON OF
ECONOMIC DATA FROM A CLINICAL TRIAL TO
A CROSS-SECTIONAL DATABASE
Crawford B, Evans C
Mapi Values, Boston, MA, USA
When economic evaluations are conducted alongside 
clinical trials estimates of resource utilization (RU) are
likely to be inaccurate. This problem arises due to pres-
ence of protocol-mandated visits and forced compliance.
It is rare to ﬁnd two databases that may be compared to
determine the scale of this problem. OBJECTIVE: 1) To
compare the resource utilization associated with rheuma-
toid arthritis from a clinical trial database to a cross-
sectional database, and 2) to understand advantages 
and disadvantages of using each database in economic
analyses. METHODS: In this novel study, two databases
were examined: one a pragmatic, cross-sectional 
database (CSD: with 6-month retrospective recall of RU)
of rheumatoid arthritis patients (RA) and the other a 
database from a phase III clinical trial program (CTD) in
RA matched on several demographic variables. Subjects
were age/gender matched to control for differences in the
database populations. Hospitalizations, GP and special-
ist visits were compared between the databases.
RESULTS: When the CTD is examined for just protocol
visits, a total of 8 specialist consultations were recorded.
When the CTD is examined for non-protocol visits, few
additional visits are recorded: 0.12 GP visits, 0.11 spe-
cialist consultations, and 0.01 hospitalizations. The addi-
tion of the non-protocol visits to the protocol total visits
increase RU to 8.12 GP visits and 8.11 specialist consul-
tations. Based on data from the CSD, over a 6-month time
frame, randomly matched on age and gender, an average
of 2.1 GP visits, 2.21 specialist consultations, and 1.3
hospitalizations were reported by patients. CONCLU-
SIONS: The inclusion of protocol-mandated visits 
substantially overstates true RU while their omission
understates thereby leaving researchers in a quandary.
The use of CTDs for modeling purposes raises the issues
of generalizability and accuracy and suggests that natu-
ralistic rather than piggyback trials should be used for PE
evaluations.
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THE PARAMETRIC BOOTSTRAP: RECONCILING
PARAMETRIC AND NON PARAMETRIC
METHODS IN THE ESTIMATION OF
CONFIDENCE INTERVALS FOR INCREMENTAL
COST-EFFECTIVENESS RATIOS?
Lilliu H
Clp-santé, Paris, France
OBJECTIVES: Many authors have addressed the issue 
of handling uncertainty in stochastic cost-effectiveness
analyses. They generally oppose parametric (Fieller’s
theorem, conﬁdence box or ellipse . . .) and non para-
metric (bootstrap) methods. The parametric bootstrap is
at the bridge of these two families of methods. Paramet-
ric bootstrap was used to assess conﬁdence interval of the
incremental cost-effectiveness ratio (ICER) of a drug used
in the treatment of post-infarction patients and the esti-
mated CI was compared to that provided by non para-
metric bootstrap. METHODS: Data were derived from a
placebo-controlled clinical trial on 1749 patients included
just after MI and followed over 4 years. Patient-level costs
were computed to reﬂect the US Health care system. The
parametric bootstrap was based on the assumption that
the incremental costs and effects differentials follow a
normal bivariate distribution. Five thousand re-samples
were made from the normal bivariate density function.
The non parametric bootstrap was based on 5000 re-
samples from the original sample. Mean ICER estimates
and percentiles CI are presented for both techniques.
RESULTS: The mean ICER from the original sample 
was estimated to US$2574 per life-year saved. The para-
metric bootstrap provided an estimated ICER of
US$2726/LYS and the 95% CI was [1164; 5210]. From
the non parametric bootstrap, the ICER estimate was
US$3419/LYS and the 95% CI was [1660; 5254]. CON-
CLUSIONS: The parametric bootstrap provided a CI,
which seemed to be in accordance with that of the non
parametric bootstrap. It still needs to be compared to
other parametric and non parametric methods, particu-
larly in terms of coverage properties. It can be a useful
tool, as it allows assumptions on the ICER joint distribu-
tion, without implying speciﬁc textbook formulae.
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THE IMPLICATIONS OF COMBINING
HETEROGENEOUS PATIENT POPULATIONS IN
META-ANALYSES
Boler A, Howard P
Heron Evidence Development, Letchworth, Hertfordshire,
United Kingdom
Systematic reviews and meta-analyses attempt to 
minimise the biases from individual trials but can, on
some occasions, miss or conceal beneﬁcial treatment
effects when trials, with varying patient populations, are
analysed together. OBJECTIVE: To investigate the effect
of ‘splitting’ diverse patient populations using part of a
published meta-analysis of randomised controlled trials
for the prevention of vascular events in high-risk patients.
METHODS: Our study re-evaluated a section of results
of a well-known meta-analysis of RCTs for the preven-
tion of vascular events. The original review (ATC) esti-
mated the combined treatment effect of dipyridamole plus
aspirin (DP + ASA) compared to aspirin (ASA) alone
using data from 25 clinical trials for all patients, regard-
less of their vascular morbidity proﬁle. Patients who had
previously experienced an MI, TIA/stroke, CABG, coro-
nary angioplasty, intermittent claudication, peripheral
